WHO Grade 3 Glioma — Trials

WHO Grade 3 Glioma — Trials · CancerIndex

Clinical trials

Registered studies

258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 57
Recruiting: 32
Ph III recruiting: 2
Growth YoY: —
Industry share: 11%
Top sponsor: National Cancer Institute (NCI)
Termination share: 39.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (53)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07215910	Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer	recruiting	Phase 3	408	Alliance for Clinical Trials in OncologyOTHER	1	Sep 2, 2026	clinicaltrials
NCT05303519	SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)(SIGMA)	recruiting	Phase 3	365	Nuvation Bio Inc.INDUSTRY	3	Aug 28, 2026	clinicaltrials